BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today ...

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog.

The subsidiary seeks damages and injunctions. Vandana Singh Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 ...

In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a decision that would remove patents related to Teva ...

BRIDGEWATER, N.J., January 29, 2025--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 BRIDGEWATER, N.J., January 23, 2025--Amneal ...

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with a price target of $11.00. The company’s shares ...

Barclays analyst Balaji Prasad maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report) today and set a price target of $10.00. The company’s shares closed last Friday at $8.68.